Table 1.
Characteristics of included prevalence studies.
| First author | Country | Published time | Type of study | Number of patients with COVID-19 | Number of COVID-19 patients with skin manifestations | Mean age |
Male/ female |
Diagnostic method |
|---|---|---|---|---|---|---|---|---|
| Bouaziz (20) | France | Apr-20 | Case series | 14 | 7 | nr | nr | PCR |
| Joob (21) | Thailand | Jan-20 | Case series | 41 | 1 | 40.5 | 4M/37F | real-time PCR |
| Joob (22) | Thailand | Mar-20 | Case series | 48 | 1 | nr | nr | RT-PCR |
| Recalcati (12) | Italy | Mar-20 | Case series | 88 | 18 | nr | nr | nr |
| Tammaro (23) | Italy | Apr-20 | Case series | 130 | 2 | nr | nr | RT-PCR |
| Zhang (24) | China | Feb-20 | Case series | 140 | 2 | 57 | 71M/69F | RT-PCR |
| Million (25) | France | May-20 | Case series | 1061 | 3 | 43.6 | 492M/569F | PCR |
| Guan (26) | China | Feb-20 | Case series | 1099 | 2 | 47 | 639M/460 F | RT-PCR |
RT-PCR, Real time-Polymerase Chain Reaction; nr, not report.